Literature DB >> 12871574

Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc.

D Stanic1, C L Parish, W M Zhu, E V Krstew, A J Lawrence, J Drago, D I Finkelstein, M K Horne.   

Abstract

Following partial substantia nigra lesions, remaining dopaminergic neurones sprout, returning terminal density in the dorsal striatum to normal by 16 weeks. This suggests regeneration and maintenance of terminal density is regulated to release appropriate levels of dopamine. This study examined the structure and function of these reinnervated terminals, defining characteristics of dopamine uptake and release, density and affinity of the dopamine transporter (DAT) and ultrastructural morphology of dopamine terminals in the reinnervated dorsal striatum. Finally, rotational behaviour of animals in response to amphetamine was examined 4 and 16 weeks after substantia nigra pars compacta (SNpc) lesions. Dopamine transport was markedly reduced 16 weeks after lesioning along with reduced density and affinity of DAT. Rate of dopamine release and peak concentration, measured electrochemically, was similar in lesioned and control animals, while clearance was prolonged after lesioning. Ultrastructurally, terminals after lesioning were morphologically distinct, having increased bouton size, vesicle number and mitochondria, and more proximal contacts on post-synaptic cells. After 4 weeks, tendency to rotate in response to amphetamine was proportional to lesion size. By 16 weeks, rotational behaviour returned to near normal in animals where lesions were less than 70%, although some animals demonstrated unusual rotational patterns at the beginning and end of the amphetamine effect. Together, these changes indicate that sprouted terminals are well compensated for dopamine release but that transport mechanisms are functionally impaired. We discuss these results in terms of implications for dyskinesia and other behavioural states.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871574     DOI: 10.1046/j.1471-4159.2003.01843.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

1.  Alterations in the proportions of skeletal muscle proteins following a unilateral lesion to the substantia nigra pars compacta of rats.

Authors:  A Sliwinski; D Stanic; D I Finkelstein; M Ilic; J M West; P C Dooley
Journal:  J Muscle Res Cell Motil       Date:  2005-07-01       Impact factor: 2.698

2.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

3.  In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment.

Authors:  LinLin Tian; Morvarid Karimi; Chris A Brown; Susan K Loftin; Joel S Perlmutter
Journal:  Brain Res       Date:  2014-05-15       Impact factor: 3.252

4.  Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys.

Authors:  Pierre-Olivier Fernagut; Qin Li; Sandra Dovero; Piu Chan; Tao Wu; Paula Ravenscroft; Michael Hill; Zhenwen Chen; Erwan Bezard
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

5.  Synaptic microcircuitry of tyrosine hydroxylase-containing neurons and terminals in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.

Authors:  Maney Mazloom; Yoland Smith
Journal:  J Comp Neurol       Date:  2006-04-01       Impact factor: 3.215

6.  Dissociation of metabolic and hemodynamic levodopa responses in the 6-hydroxydopamine rat model.

Authors:  Renata P Lerner; Zisis Bimpisidis; Stergiani Agorastos; Sandra Scherrer; Stephen L Dewey; M Angela Cenci; David Eidelberg
Journal:  Neurobiol Dis       Date:  2016-08-17       Impact factor: 5.996

7.  Task-rest modulation of basal ganglia connectivity in mild to moderate Parkinson's disease.

Authors:  Eva M Müller-Oehring; Edith V Sullivan; Adolf Pfefferbaum; Neng C Huang; Kathleen L Poston; Helen M Bronte-Stewart; Tilman Schulte
Journal:  Brain Imaging Behav       Date:  2015-09       Impact factor: 3.978

8.  Thalamic mediation of hypoxic respiratory depression in lambs.

Authors:  Brian J Koos; Arezoo Rajaee; Basil Ibe; Catalina Guerra; Lawrence Kruger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-01-27       Impact factor: 3.619

9.  Persistence of intact retinal ganglion cell terminals after axonal transport loss in the DBA/2J mouse model of glaucoma.

Authors:  Matthew A Smith; Christina Z Xia; Christine M Dengler-Crish; Kelly M Fening; Denise M Inman; Brett R Schofield; Samuel D Crish
Journal:  J Comp Neurol       Date:  2016-05-03       Impact factor: 3.215

10.  The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease.

Authors:  Lin W Hung; Victor L Villemagne; Lesley Cheng; Nicki A Sherratt; Scott Ayton; Anthony R White; Peter J Crouch; SinChun Lim; Su Ling Leong; Simon Wilkins; Jessica George; Blaine R Roberts; Chi L L Pham; Xiang Liu; Francis C K Chiu; David M Shackleford; Andrew K Powell; Colin L Masters; Ashley I Bush; Graeme O'Keefe; Janetta G Culvenor; Roberto Cappai; Robert A Cherny; Paul S Donnelly; Andrew F Hill; David I Finkelstein; Kevin J Barnham
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.